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Trimethylpsoralen (TMP) levels in the blood of vitiligo 
patients were determined through the use of a high-
performance liquid chromatographic method. TMP was 
extracted from blood buffered at pH 9.0 with 95:5 (V IV) 
hexane-isopropanol mixture; evaporated to dryness, and 
reconstituted in 50 /LI of ethanol. A 10-/LI aliquot was 
injected into a Micropack MCH-10 column (Varian HPLC 
model #5000). The mobile phase consisted of a mixture 
of water and acetonitrile with a linear gradient. The 
retention time of TMP was 16.5 min. The calibration 
curve of the external standards was linear. Overall re-
covery ofthe internal stands was 75-92%, with the lower 
detection limit of TMP at 2 ng/mI. Peak blood levels as 
low as 140 ng/ml and as high as 800 ng/mI were obtained 
in vitiligo patients 1-2 hr following the oral administra-
tion of 30 mg of trioxsalen tablets (Paul B. Elder Co.). 
Blood TMP levels peaked consistently at 2 hr when pa-
tients were fasted for 8 hr prior to drug ingestion. These 
results are consistent with the clinical observation that 
maximum response due to phototherapy is obtained 1-2 
hr after oral administration of the drug. Two hours after 
oral drug administration, TMP levels in the epidermis, 
dermis, and whole skin of the guinea pig (in ng p er g 
tissue ) were: epidermis, 226 ± 15; dermis, 25 ± 6; and 
whole skin 176 ± 12. Also detected were TMP leve ls 244 
± 17 ng/ml in aqueous humor and 63 ± 6 mg/ mI in 
vitreous humor. These results point to the fact that the 
eyes of patients must be protected from overexposure to 
sunlight after psoralen-ultraviolet treatment. 
Photochemotherapy (PUV A), using 4,5'8-trimethylpsoralen 
(TMP) and ultraviolet radiation (UVA), has been reported as 
a reasonably successful modality of treatment for vitiligo [1-
6]. Kligman and Goldstein [7], however, reported that up to 200 
mg of oral trioxsa~n had no effect with long-wave UV rays. 
These investigators obtained mild phototoxic responses with 1-
hr exposure to sunlight after oral administration of 200 mg 
(minimum) of trioxsalen. They concluded that claims of thera-
peutic value of trioxsalen probably reflect observer enol'. They 
also indicated that the drug is either not absorbed or, less likely, 
is metabolically degraded. Subsequently, Kaidbey and Kligman 
[8J reported that irradiation with long-wave UV rays, 2 hr after 
ingestion of 90 mg of trioxsalen produced pigmentation without 
a preceding visible inflammatory reaction. It appears, therefore , 
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that the dI'ug is absorbed from the gastrointestinal tract sin ce, 
orally administered, TMP seems to be effective in producing 
photopigmentation. However, it is not known when peak blood 
or t issue TMP levels OCCill' after oral administration. 
Several authors [9-14] have reported methods for t he deter-
mination of B-methoxypsoralen (B-MOP) in blood. We have 
found only one report [15J that deals with the determination of 
trioxsalen in blood after oral ingestion, as well as after trioxsalen 
bath treatment. Methods used were gas-chromatographic and 
mass fragmentation. These authors reported blood levels of 
TMP to be 2-3 ng/ml after bath treatment and negative in all 
patients after oral administration. Controversies exist as to 
whether or not trioxsalen is absorbed from the gastrointestinal 
tract [7,8,15-18J and its therapeutic effectiveness. One of the 
pill'poses of this report is to demonstmte that trioxsalen is in 
fact absorbed systemically from the gastrointestinal tract. 
Carter and his associates [11,12] measured plasma 8-MOP in 
psoriatic patients on PUV A therapy, using high-pl'essure liquid 
chromatography (HPLC) with a microparticulate normal phase 
silica gel column. These investigators reported retention times 
of B-MOP and TMP to be 4.2 and 4.5 min, respectively. The 
retention times of the two drugs were so close that they almost 
overlapped. In addition, TMP measw'ement was not reported 
by these auth ors [11,12]. (We used a reversed phase column in 
order to obtain better qualitative separation of the two dl'ugs, 
as well as for quantitative measw'ements ofTMP using HPLC.) 
T he present report involves the quantitative meaSill'ement of 
TMP in t he blood of vitiligo patients after ingestion of trioxsalen 
tablets (Paul B. Elder Co.) . Also, TMP was measured in the 
. homogenates of epidermis, dermis, and whole skin, as well as in 
ophthalmic fluids of the guinea pig. 
In addi tion to accurate TMP measurement methods for 
blood, skin, and ophthalmic fluids, other factors have been 
noted: (1) therapeutic value of trioxsalen absorption from the 
gastrointestinal tract; (2) possible ophthalmic risks of trioxsalen. 
MATERIALS AND METHODS 
Patients 
Blood TMP levels of 11 patients (7 male, 4 female) were determined 
after written informed consent was obtained. Ten-milliliter blood sam-
ples were drawn prior to oral administration of 6 5-mg trioxsalen 
tablets. After drug ingestion the samples were drawn at hourly intervals 
up to 4 hI' and at 24 hr. Similarly, 4 patients (2 male, 2 female) were 
administered 0.6 mg/ kg. TMP levels were determined after the subjects 
fasted. 
An.im.als 
Guinea pigs were used as an animal model in this study for photo-
biologic experiments. In addition, the guinea pig was used for measw'e-
ments ofTMP in whole skin, epidermis, dermis, and ophthalmic fluids 
2 hr after oral administration of 10 mg of trioxsalen. Hail' was removed 
from the whi te areas of spotted guinea pigs and the areas were marked 
into 2-cm squares. Each square was used for application of: 0.1 m1 of 
0.1% TMP, 0.1 ml of 0.5% 8-MOP, 0.1 ml of' propylene glycol ethanol 
mixture (as a blank) , and 0.1 ml of the material extracted fTom the 
blood. All topical applications were made in triplicate. Thirty minutes 
after application, the animals were exposed to a high-intensity (UVA) 
radiation source (Psora lite, Paul B. Elder Co.). Total dose applied was 




Crystalline trimethyJpsoraJen or trioxsalen (TMP) and crystalline 
methoxsalen (S-MOP) were obtained from Sigma Chemical Co. , St. 
Louis, MissoW"i. Acetonitrile, HPLC grade, and all other a nalytical-
grade solvents and chemicals were pW"chased from Fisher Scientific 
C o., S ilver Spring, Maryland. 
A ssay Method 
The extraction procedW"e was a slight modification of a technique 
d escribed by Puglisi et al [9] for extraction of 8-MOP from blood. A 2-
m l blood sample was mixed with 5 ml of 1 M sodium borate buffel· (pH 
9.0). Sixteen milliliters of a mixtW"e of n-hexane:isopropanol (95:5) was 
added at room temperatw·e. T he mixture was shaken on a reciprocating 
s haker for 30 min at 70-80 strokes/min. After centrifugation for 20 min 
at 1020 x g, 10 ml of the organic layer was transferred to a scintillation 
vial and evaporated to dryness under a stream of dry nitrogen. Just 
prior to HPLC analysis, the dry residue was reconstituted in 50 iLL 
a bso lu te ethanol, and 10 iLL was injected on the chromatographic 
column. For the measW"ement of TMP levels in whole skin, epidermis, 
and dermis, the t issues were homogenized in 1 M sodium borate buffer 
(pH 9.0). TMP was extracted as described. The ophthalmic fluids were 
treated as the blood for extraction and measW"ement of TMP. 
Chromatographic Parameters 
The instrument used for this process was a Varian (Model #5000), 
high-pressW"e liquid cm·omatograph, equipped with a 254- 280 nm UV 
detector; operated at 254 nm, with a 10-,...1 loop injector. The analytical 
column was a prepacked 30 em x 4 mm Varian Micropa k (MCH-10) 
containing Reverse P hase Vydac. The mobile phase consisted of a 
mixtW"e of water and acetonitrile with a linear gradient at a flow rate 
of2 ml/ min. The detector sensitivity was set at 0.01 AU while the chart 
speed on the 1-mV Vru·ian recorder (Model #9176) was 1 em/ min. 
A nalytical Stan.dards and Preparation of Calibration Curves 
A stock solution of standru·d TMP was prepru·ed by dissolving 100 
mg of analytical-grade trioxsalen in 10 ml of absolute ethanol. Suitable 
dilu tions of this s tandard having a TMP concentration of 1 mg/ ml were 
ruso prepru·ed in absolute ethanol. A series of [W"ther dilutions was 
made from the latter so that 10 iLl (injected onto the column) contained 
2,4, 5, 8, 10, and 12 ng of TMP. 
For recovery studies, enough TMP was added to 2 ml of blood 
samples so that the final concentrations were 4, 8, 10, and 12 ng per ml. 
The ill·ug was then extracted from each sample as outlined in Assay 
M ethod. 
RESULTS 
The retention time of TMP in our analytical procedure was 
16.5 min which, with the retention time of 8 min for the 8-MOP, 
was used as an internal standard. Table I shows the relationship 
between the peak heights in cm and the amounts of TMP (in 
ng) injected onto the chromatographic column. Each point was 
established from an average of 7 determinations. As seen in 
Table I, a fairly linear relationship was obtained from external 
standards. 
The amounts of TMP added to, and recovered from, blood 
varied fTom 75-92%. When 4.0 ng was added, per ml 3.3 ± 0.3 
ng (83%) was recovered. Similarly, for 8.0 ng, 10.0 ng, and 12.0 
ng of TMP added per m1 of blood, the respective recoveries 
were 6.0 ± 0.6 (75%),8.0 ± 0.9 (80%), and 11.0 ± 1.2 (92%). 
Blood TMP levels at different times after oral administration 
of 30 mg of trioxsalen were determined and the results are 
TABLE 1. Relationship between. the amount of TMP injection. into 
HPLC column and the p eah heights 







Peak heights (cm) 
1.6 ± 1.2 
3.9 ± 0.4 
4.5 ± 0.5 
7.S ± O.S 
8.5 ± 0.9 
11.5 ± 1.2 
TMP (2,4,5,8, 10, and 12 ng) was injected onto the chromatographic 
column and elu ted peak heights were recorded. For details, see Mate-
rials and Methods. Each poin t is an average of 7 determinations. 
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TABLE II. Blood TMP levels in human subjects after ingestion of 30 
mg trioxsalen. 
Subjects Time course of 'I'M? recovered from patients' blood (ng/ ml) 
Sex Age o hr I hr 2 hr 3 hr 4 hr 24 hr 
F 54 0 444 46 80 40 120 
M 56 0 450 34 51 31 80 
M 39 0 36 460 57 80 55 
M 36 0 530 74 105 67 113 
F 64 0 570 31 38 13 70 
M 73 0 46 600 49 36 60 
F 49 0 140 29 38 30 42 
M 54 0 14 800 27 23 36 
F 30 0 195 40 37 40 40 
M 29 0 23 600 52 48 80 
M 67 0 5S0 36 44 19 47 
*F 47 0 46 411 28 22 27 
*M 41 0 39 224 25 24 33 
*F 65 0 28 280 22 23 40 
*M 28 0 95 242 58 47 50 
Ten milliliters of blood was ill·awn in a heparinized tube from each 
subject prior to oral administration of 6 5-mg trioxsalen tablets. After 
the drug in take, 10 ml of blood was ill·awn at homly intervals up to 4 m· 
and fmally the next day, at 24 lu. Extraction and ana lysis of TMP is 
described in Materials and Methods. 
* T he last 4 subjects were fasted for S hr or more prior to the drug 
ingestion. 
presented in Table II. As can be seen, wide variations of blood 
TMP levels were observed. However, t he results indicate that 
peak blood level was only 140 ng/ lnl. Other patients absorbed 
the drug readily and peak blood levels of up to 800 ng/ml could 
be found. Additionally, it can be noted that blood TMP levels 
in some patients were somewhat higher at 24 hr as compared 
to the levels at 3 or 4 hr. 
In order to determine whether food intake affects absorption 
of TMP, 4 patients (2 female, 2 male) were fasted for at least 8 
hr prior to, and 4 hr after dmg ingestion. The TMP levels 
obtained in these patients are also shown in Table II (last 4 
patients) . Peak blood TMP levels after oral administration of 
0.6 mg/ kg of trioxsalen in these subjects varied considerably. 
However, peak levels in all subjects occurred at 2 hr after drug 
ingestion in this group. 
Presented in Table III, are the TMP levels of ophthalmic 
fluids 2 hr after oral administration of the drug (10 mg/ kg) in 
the guinea pigs. Aqueous humor was drawn from the anterior 
chamber of the eye into a syringe with a 26-gauge needle. The 
volume of fluid obtained from each eye was about 0.1 mI. T he 
vitreous fluid was drawn from the posterior chamber of the eye 
of the guinea pig, using a 16-gauge needle. The volume of this 
fluid was about 0.8 mI per eye. The extraction and determina-
tion of TMP were performed as for the blood. Two homs after 
the drug administration, the TMP concentration in the aqueous 
humor was found to be about 5 tinles higher than in the vitreous 
humor. 
Similarly, 2 hr after oral administration of 10 ml/ kg of TMP, 
concentrations ofTMP in the whole skin, dermis, and epidermis 
were determined in the guinea pigs. After sacrifice, 1 g of whole 
skin was homogenized in 5 ml of 1.0 M sodium borate buffer, 
pH 9.0, and TMP was extracted from the whole homogenate. 
For the determination of TMP in the epidermis and dermis, 10 
g of skin was cut into l -cm squares and soaked in 0.1% NH40H 
solution at ambient temperatw'e for 1 hr. The epidermis was 
then separated from the dermis. One gram of each tissue was 
then separately homogenized, using the procedure as for the 
whole skin. The extraction and analysis of TMP were similar to 
the treatment of the whole skin. TMP levels found in these 
tissues were: whole skin, 176 ± 12; dermis, 25 ± 6; epidermis, 
226 ± 15 per g, respectively. The results represent duplicate 
analyses from 3 different animals. 
In order to determine whether the compound extracted from 
the blood and measUl"ed by HPLC was photobiologically active, 
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TABl>E III. TMP levels in ophthalmic fluids after oral ingestion of 
10 mg of trioxsalen in the guinea pigs 
Animals 
TMP recovered from eye nuid 
(ng/ml) 
Aqueous humor Vitreous humor 
Guinea pig #1 
Guinea pig #2 







Aqueous humor (lens Quid) was obtained from guinea pig lens with 
a tuberculine syringe attached with a I6-gauge needle, while vitreous 
humor was drawn from the space between retina and lens with a 26-
gauge needle. Ophthalmic fluids were obtained 2 hr after oral admin-
istration of 10 mg/ kg TMP. The fluids obtained from separate animals 
without the drug administration showed no TMP in these fluids. TMP 
was extracted and analyzed accord ing to the descrip tion for blood in 
Materials and Methods. 




24 h1" 48 hr 72 Ill· 
Control (no UV radiation) (black tape) none none none 
Mixture of propylene glycol:absolute none none none 
ethanol (30:70) 
TMP (0.1%) + + + 
TMP (0.5%) + ++ ++ 
8-MOP (0.5%) + + + 
Material extracted from blood + + + 
" Average from observations on 3 different guinea pigs: + = ery-
thema; ++ = erythema and edema. 
TMP, B-MOP, and the material extracted from blood were dissolved 
in a mixture of propylene glycol:ethanol (30:70 vol). T he 0.1 ml of each 
solution was applied on 2-cm squares of marked skin surface 30 min 
prior to exposure to (1.2 J /cm2 ) UVA in a Psorali te box. Phototoxic 
responses were noted 24,48, and 72 hr later. 
experiments were conducted, using the guinea pig as the test 
animal. The material extracted from the blood was pooled, 
evaporated to dryness, and reconstituted in 0.3 ml of a mixture 
of 30% propylene glycol, 70% ethanol. Table IV shows the 
results of photobiologic effects produced on guinea pig skin 
from the material extracted from the patients' blood . Phototoxic 
responses were produced consistently and were similar to the 
responses produced by the psoralens. 
The criteria used to establish the positive identity of the 
compound extracted from blood was cochromatography, gas-
chromatography, .and mass-spectrometry. Cochromatography 
was run with TMP on thin-layer plates in 2 separate solvents 
(90:10 benzene-ethylacetate by vol and ethyl acetate: 
chloroform:acetone:methanol:acetic acid: 5:5:3:1:1 by vol). By 
gas-chromatography, the material was eluted at an identical 
position as authentic TMP. The mass-spectral fTagmentation 
of the extracted material was also identical to that of authentic 
TMP, producing masses at 228, 200, 185, 170, 157, and 128 
daltons by elimination of CO2, CHa, etc. 
DISCUSSION 
Peak blood TMP levels achieved in 1-2 hr in our study are 
in agreement with the observation that the maximum photo-
biologic effect is produced when subjects are irradiated with 
long-wave UV radiation 2 hr after ingestion of the drug [1-6). 
Murata et al [19], who studied distribution of [3H]-trioxsalen in 
the rat, found that peak radioactivity in the blood was obtained 
at 2 hr; then the level fell steadily during a period of t ime up to 
48 hr. These investigators found blood bvels as high as 4 p.g per 
g of blood (which is roughly 4000 ng/ml), although the dosages 
used were high (either 200 mg or 10 mg per kg) . We found, in 
human subjects, the peak blood levels were 140-800 ng/ml, 
which is not inconsistent with their findings in the rat [19]. We 
are unable to explain the observation made by Fischer et al [15] 
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that orally administered TMP could not be detected in blood 
using methods of solvent extraction and analysis of TMP by 
gas-chromatography and mass-spectrometic fTagmentation. It 
is possible that their method of extraction was ineffective since 
they found blood TMP levels of 2-3 ng/ml after trioxsalen bath 
treatment. It is c1ifficult to comprehend that the orally admin-
istered drug was not absorbed in the blood and skin (15). 
Kligman and Goldstein [8] suggested that trioxsalen may be 
very rapidly metabolized. Indeed, Mandula, Pathak, and Dudek 
reported rapid oxidation of TMP to 4,8-dimethyl, 5' -carboxy-
psoralen [20,21] by liver t issue, but not by the epidermis [21). 
Furthermore, TMP in combination with exposure to long-wave 
UV radiation has been shown by the same authors to be 
effective in treating patients with disabling, generalized pso-
riasis and patients with vitiligo who have lost normal melanin 
pigmentation of their skin [22). Hence, rapid metabolism does 
not rule out total effectiveness of TMP. 
Many of the photobiologic effects of psoralens are explained 
on the basis of the formation of DNA-psoralen photoadducts in 
the epidermal cells, photoexcitation of psoralens to singlet and 
triplet states, and generation of free radicals in the skin, which 
can damage the cell membrane [22]. However, it has never been 
explained satisfactorily why, on the one hand, the keratinocyte 
proliferation is inhibited (presumably due to inhibition of DNA 
duplication), while on the other hand, the pigment cell prolif-
el·ation and pigment synthesis al·e enhanced by PUV A therapy. 
Other investigators reported on methods of determination of 
8-MOP [9-14], and noted wide variations of blood 8-MOP 
levels. Some of these val·iations may be due to differences in 
active transport or psoralen binding sites in the gastrointestinal 
tract and other target tissues and fluids of individual patients. 
The differences may be due also to food intake and other 
uncontrolled variables. In our finding, although individual blood 
levels differed when patients were fasted, peaking of TMP in 
blood occurred at 2 hr in all 4 patients (2 female, 2 male) 
studied, which indicates a steady rate of absorption under this 
condition. 
The correlation between blood TMP levels, the time at which 
peak blood levels occur, and the skin photosensitivity have not 
yet been established. Establishment of this relationship will 
enable clinicians to treat extensively involved vitiligo patients 
by oral psoralens and UV A most effectively. Recently, Ljung-
gren and his associates [12] showed a lineal· relationship be-
tween dosage of 8-MOP and serum level of the drug in 8 human 
subjects. Our present work suggests that a similal· study can 
and should be done after oral TMP administration. 
We found significant TMP accumulation in the whole skin 
and epidermis. In the dermis, however, concentration was much 
lower. Murata et al (19) measured CH)-TMP in the whole skin 
of the rat after 200 mg/g and 10 mg/g oral doses of [3H]-TMP, 
and found that in whole skin the TMP level was as high as 1 
p.g/g of the tissue. These investigators did not measure TMP in 
the epidermis and dermis separately, however. Our finding of a 
9-fold higher accumulation of TMP in the epidermis of the 
guinea pig, as compared to the dermis, may be due to an active 
binding site for psoralens in this tissue (especially in pigment 
cells). The rapid turnover of epidermis may also be a factor in 
the high accumulation of the drug. 
We found that TMP was accwl1ulated both in aqueous humor 
as well as in vitreous humor of guinea pigs. The concentrat.ion 
was 5-fold higher in aqueous humor as compared to vitreous 
humor. The role of UV radiation in the pathogenesis of senile 
cataracts and the effects of psoralens have been documented. 
[23-25]. To our knowledge there have been no reports involving 
measurements of trioxsalen in ophthalmic fluids. However, 
Lerman and Borkman [26] demonstrated accumulation of 8-
MOP in rat lens after intraperitoneal injection of the drug, and 
the concentration found was of the order of lO- "M (i.e., 2160 
ng/ml). Fitzpatrick and associates [1] reported measurements 
of 8-MOP in the aqueous humor, vitreous humor, and crystal-
line lens of either guinea pigs or rabbits after oral administration 
of 10 mg/kg of methoxsalen. The results reported by these 
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authors appear to be in conflict, stating, " ... no evidence of the 
presence of these compounds in t he aqueous humor, the crys-
talline lens or the vitreous humor," but on t he other hand they 
reported, " ... as little as 10- (; molar concentration can be 
detected by spectrofluorometry." A concentration of 10- 6 M is 
t he same as 1 !-1M, which is 216 !-Ig 8-MOP / liter (0.216 !-Ig/ ml or 
216 ng/ ml). Our finding is that TMP (not methoxsalen) concen-
tration in aqueous humor is about 240 ng. T his is not inconsis-
tent with the finding of Fitzpatrick et al [1] that concentrations 
of psoralens in ophthalmic fluids are of the order of 10- (; M. 
Recently, Willis and his associates reported rapid induction 
of cancers in hairless mice by photoaugmentation [27). Om 
fi nding that high concentration of TMP occurs in guinea pig 
ophthalmic fluids and epidermis suggests that th e combined 
effect of psoralens and UV radiation may cause additional risk. 
The compound isolated from blood had photobiologic activity 
s imila]' to psoralens on the guinea pig skin and the extracted 
compound was positively identified as TMP by thin-layer cru'o-
matography and by gas cru'omatography-mass spectrometry 
criteria. 
In summary, an HPLC method has been developed for t he 
measurements of TMP in blood, ophthalmic fluids, epidermis, 
a nd other t issues, The lower limit of sensitivity of the method 
is 2 ng. TMP is preferentially localized in certain body fluids 
a nd tissues, indicating existence of a psoralen receptor macro-
molecule. 
The authors are indebted to Daniel M. Albert, M.D. of the Massa-
c husett.s Ear & Eye Infirmary for showing the technique of obtaining 
ophthalmic fluids from guinea pig eyes, and to Ms. Theresa Dryden for 
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